Molecular profiling in CLL.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic lymphocytic leukemia (CLL) presents a highly variable clinical course.
• Understanding the molecular basis of this heterogeneity is crucial for predicting patient outcomes and disease pathogenesis.

Purpose of the Study:

• To review the prognostic significance of clinical and molecular biomarkers in CLL.
• To discuss the integration of these biomarkers into clinical practice and treatment decisions.

Main Methods:

• Review of established clinical parameters.
• Analysis of molecular biomarkers including cytogenetics by fluorescent in situ hybridization (FISH), immunoglobulin heavy chain (IgVH) mutational status, and ZAP70 expression.

Main Results:

• Clinical parameters and molecular biomarkers (FISH, IgVH, ZAP70) are validated predictors of CLL clinical course.
• Current consensus favors treating symptomatic CLL, with high-risk features prompting further clinical trials.

Conclusions:

• Molecular biomarkers provide valuable prognostic information for chronic lymphocytic leukemia.
• The optimal use of high-risk features in guiding treatment decisions requires further investigation through clinical trials.